In addition to the kinase solution and epigenetics assays, HDB also provides high-quality services including assay development and screening against enzyme targets including but not limited to phosphodiesterases (PDEs), protease, ATPase, integrase, polymerase, ubiquitinase, deubiquitinase and dehydrogenase.

As the important regulators of signal transduction mediated by second messenger molecules such as cAMP and cGMP, PDEs are often targets for pharmacological inhibition due to their unique tissue distribution, structural properties, and functional properties. Applying Perkin Elmer’s LabChip platform, HDB provides screening and profiling services

cAMP PDEs are emerging as a promising class of drug targets in asthma and cardiovascular disease therapeutic areas. HDB has established the cell-based screening assay for cAMP phosphodiesterase (PDE) inhibitors in HDB based on the Codex ACTOne™ technology. The specificity of the assay has been verified by known PDE inhibitors. Only PDE4 and pan-PDE inhibitors showed positive signals in the cell line that was optimized for

We provide custom biochemical or cell-based assay development for other enzymes that